Evidence map›Paper›PMID 38073130›Full record

ArticleMolecular oncology2025

Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product.

Michiel Stevens, Anouk Mentink, Frank A W Coumans, Eshwari Dathathri, Khrystany T Isebia, Jaco Kraan, Ronald de Wit, John W M Martens, Leon W M M Terstappen

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michiel StevensDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0001-8643-7235
Anouk MentinkDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
Frank A W CoumansDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0001-6282-6009
Eshwari DathathriDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0001-9389-029X
Khrystany T IsebiaDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-3006-5206
Jaco KraanDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-7445-7984
Ronald de WitDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-1954-090X
John W M MartensDepartment of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-3428-3366
Leon W M M TerstappenDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.ORCID https://orcid.org/0000-0001-5944-3787

Funding

Nederlandse Organisatie voor Wetenschappelijk Onderzoek 17915
6 · The paper itself

Abstract

The clinical utility of circulating tumor cells (CTCs) is hampered by the low number of cells detected. Diagnostic leukapheresis (DLA) offers a solution but, due to the observed non-specific binding and clumping, processing of DLA samples using the CellSearch system only allows for the processing of aliquots consisting of ~ 2% of the total DLA sample per test. Here, we introduce a flow enrichment target capture Halbach-array (FETCH)-based separation method in combination with a DNase preprocessing step to capture CTCs from larger fractions of DLA products without clumping. To evaluate the FETCH method, we processed peripheral blood samples from 19 metastatic castration-naïve prostate cancer (mCNPC) patients with CellSearch, and processed 2% aliquots of leukapheresis samples from the same patients with CellSearch as well as FETCH with or without DNase preprocessing. Using 2% aliquots from six patients, the use of FETCH with fewer immunomagnetic epithelial cellular adhesion molecule (EpCAM) conjugated ferrofluids was tested, whereas 20% aliquots from four patients were used to evaluate the processing of 10-fold larger DLA samples using FETCH. Results show that the cell clumping normally seen after immunomagnetic enrichment of DLA material was greatly reduced with the use of DNase pretreatment, while the number of CTCs detected was not affected. The number of CTCs detected in 2% aliquots of DLA using FETCH was unchanged compared to CellSearch and did not decrease when using down to 10% of the volume of immunomagnetic anti-EpCAM ferrofluids normally used in a CellSearch test, whereas the number of co-enriched white blood cells reduced a median 3.2-fold. Processing of a 20% aliquot of DLA with FETCH resulted in a 14-fold increase in CTCs compared to the processing of 2% aliquots of DLA using CellSearch and a total 42-fold median increase in CTCs compared to peripheral-blood CellSearch.

Indexed as

Immunomagnetic SeparationLeukapheresisNeoplastic Cells, CirculatingProstatic NeoplasmsHumansMalecirculating tumor cellsdiagnostic leukapheresisflow enrichmentmagnetic enrichment

Identifiers

PMID38073130
PMCPMC12234375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.